NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=151931&from=3 CLASS PERIOD: Ju ...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Fortrea Holdings Inc. (NASDAQ: FTRE)?Did you purchase your shares between July 3, 2023 and February 28, 2024, inclusive?Did you l ...

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fortrea Holdings Inc. (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025, both dates inclusive (the "Class Period"), have until August 1, 2025 to seek appointment as lead plaintiff of the Fortrea class action lawsuit.  Captioned Deslande v. Fortrea Holdings Inc., No. 25-cv-04630 (S.D.N.Y.), the Fortrea class action lawsuit charges Fortrea and certain of Fortrea's top executive ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fortrea Holdings Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements during the class period from July 3, 2023, to February 28, 2025 [1] Allegations - The complaint alleges that Fortrea overestimated the revenue contributions from its long-term projects, known as the Pre-Spin Projects, to the company's 2025 earnings [1] - It is claimed that Fortrea overstated the cost savings expected from exiting transition services agreements [1] - The company's previously announced EBITDA targets for 2025 were allegedly inflated as a result of these misstatements [1] - The viability of Fortrea's post-spin-off business model and its financial prospects were also overstated [1] - Consequently, the company's public statements were materially false and misleading throughout the relevant period [1] Next Steps for Shareholders - Shareholders who purchased shares of FTRE during the specified timeframe are encouraged to register for the class action by August 1, 2025 [2] - Upon registration, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2] - Participation in the case incurs no cost or obligation for the shareholders [2] About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, stemming from allegations of overstating cost savings and revenue projections related to transition services agreements following its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions [3]. - The company was spun off from Labcorp Holdings Inc. in June 2023, becoming a standalone publicly traded entity [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that Fortrea exaggerated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing financial results for Q4 and full year 2024, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from July 3, 2023, to February 28, 2025, seeking damages for misleading statements regarding the company's business and financial prospects [1][5]. Company Overview - Fortrea Holdings, Inc. is a global contract research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [3]. - The company was spun off from Labcorp Holdings Inc. in June 2023, becoming a standalone publicly traded entity [3]. - Fortrea claims to have the scale and expertise to deliver tailored solutions to its customers, with a portfolio of long-term projects that provide visibility into future revenues [3][4]. Financial Performance and Projections - In March 2024, Fortrea targeted an adjusted EBITDA margin of approximately 13% for 2025, which was later revised to a range of 11% to 12% in August 2024, still representing a projected increase of 30% to 40% in adjusted EBITDA dollars [5]. - Following the class action allegations, Fortrea's financial performance has been called into question, with claims that the company overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting transition services agreements (TSAs) [5][10]. Market Reactions and Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in the company's business model amid pressures on biotechnology funding [6][7]. - Following a downgrade by Baird Equity Research on December 6, 2024, Fortrea's stock price fell significantly due to concerns about the company's communication and performance post-spin [8]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligning with prior expectations, leading to a substantial drop in stock price [9]. Credit Rating and Future Outlook - After the Class Period, Fitch Ratings downgraded Fortrea, projecting a 2025 EBITDA margin of 7.0% to 8.0%, a significant decline from earlier projections of 11% to 13% [10].

Core Viewpoint - A class action has been filed against Fortrea Holdings, Inc. for allegedly misleading investors regarding the progress of its pre-spin projects and financial expectations [1][2][4]. Group 1: Company Background - Fortrea Holdings, Inc. is a global contract research organization (CRO) that provides biopharmaceutical product and medical device development solutions [1]. - The company was spun off from Labcorp Holdings Inc. in June 2023 and operates under several transition services agreements with Labcorp [2]. Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA trajectories for 2025 were not in line with prior expectations, leading to a significant stock price drop of $3.47 per share, or 25.05%, closing at $10.38 [3]. - The company indicated that its pre-spin projects were late in their life cycle, resulting in lower revenue and profitability than expected for 2025 [3]. Group 3: Allegations and Misstatements - The complaint alleges that Fortrea overestimated the revenue contributions from pre-spin projects and overstated potential cost savings from exiting transition services agreements [4]. - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, which misrepresented the viability of its post-spin business model and financial prospects [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fortrea Holdings Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by August 1, 2025 [2][4]. Company Overview - Fortrea Holdings Inc. (NASDAQ: FTRE) is under scrutiny for allegedly making false or misleading statements regarding its financial performance and business model [4]. - The company has faced significant stock price declines following negative reports and announcements, indicating potential weaknesses in its business model and financial projections [5][6][7]. Financial Performance - Fortrea's stock price fell by $2.73 (12.29%) to $19.48 on September 25, 2024, after Jefferies downgraded the stock from buy to hold, citing concerns over the company's business model and cost savings [5]. - Following a downgrade by Baird Equity Research on December 6, 2024, the stock price dropped by $1.90 (8.06%) to $21.67, attributed to concerns about the company's communication and sector challenges [6]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, leading to a stock price decline of $3.47 (25.05%) to $10.38 [7]. Legal Proceedings - A federal securities class action has been filed against Fortrea, and investors who suffered losses are encouraged to contact Faruqi & Faruqi for potential legal recourse [2][4][9]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the deadline for applications set for August 1, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from July 3, 2023, to February 28, 2025, seeking damages for misleading statements regarding the company's business and financial prospects [1][6]. Company Overview - Fortrea is a global contract research organization (CRO) that provides biopharmaceutical product and medical device development solutions to various customers [4]. - The company was spun off from Labcorp Holdings Inc. in June 2023, becoming a standalone publicly traded entity [4]. - Fortrea claims to have the scale and expertise to deliver tailored solutions to its customers, with a focus on operational agility and financial flexibility [5]. Financial Performance and Projections - In March 2024, Fortrea targeted an adjusted EBITDA margin of approximately 13% for 2025, which was later revised to a range of 11% to 12% in August 2024, still representing a projected increase of 30% to 40% in adjusted EBITDA dollars [6]. - The lawsuit alleges that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting transition services agreements (TSAs), leading to inflated EBITDA targets [6]. Market Reactions and Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in the business model amid pressure on biotechnology funding, resulting in a stock price drop of 12.29% [8]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral on December 6, 2024, leading to an 8.06% decline in stock price [9]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA trajectories for 2025 were not aligned with prior expectations, causing a significant stock price drop of 25.05% [10]. Credit Rating and Future Outlook - After the Class Period, Fitch Ratings downgraded Fortrea, projecting a 2025 EBITDA margin of 7.0% to 8.0%, a significant decline from earlier targets of 13% and 11%-12% [11].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its financial performance and business model [1][4]. Group 1: Lawsuit Details - The lawsuit is initiated by the Schall Law Firm, focusing on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Fortrea's securities between July 3, 2023, and February 28, 2025, are encouraged to participate in the lawsuit before the deadline of August 1, 2025 [2]. Group 2: Allegations Against Fortrea - The complaint alleges that Fortrea overestimated potential revenue from projects initiated before its spinoff from Labcorp Holdings Inc. [4]. - The company is accused of overstating cost savings from exiting transition services agreements, leading to inflated EBITDA targets [4]. - Overall, the lawsuit claims that Fortrea's public statements were materially misleading, resulting in investor losses when the truth was revealed [4].